# Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

> **NCT02761057** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 152 (actual)

## Conditions studied

- Locally Advanced Papillary Renal Cell Carcinoma
- Metastatic Papillary Renal Cell Carcinoma
- Stage III Renal Cell Cancer AJCC v7
- Stage IV Renal Cell Cancer AJCC v7
- Type 1 Papillary Renal Cell Carcinoma
- Type 2 Papillary Renal Cell Carcinoma
- Unresectable Renal Cell Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **DRUG:** Cabozantinib S-malate
- **PROCEDURE:** Computed Tomography
- **DRUG:** Crizotinib
- **DRUG:** Savolitinib
- **DRUG:** Sunitinib Malate

## Key facts

- **NCT ID:** NCT02761057
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-25
- **Primary completion:** 2023-10-19
- **Final completion:** 2023-10-19
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2025-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02761057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02761057, "Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT02761057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*